Control of biofilm formation: Antibiotics and beyond

Applied and Environmental Microbiology

Volumn 83, Issue 3, 2017, Pages

  Algburi, Ammar ^a,b   Comito, Nicole ^a   Kashtanov, Dimitri ^c   Dicks, Leon M T ^d   Chikindas, Michael L ^c,e  

^a The State University of New Jersey   (United States)

^b UNIVERSITY OF DIYALA   (Iraq)

^c RUTGERS UNIVERSITY   (United States)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e the State University of New Jersey   (United States)

Author keywords

Biofilms; Complementary medicines; Integrative approach; Natural antimicrobial products

Indexed keywords

ANTIMICROBIAL AGENTS; BIOFILMS; CONTROLLED DRUG DELIVERY; DISEASE CONTROL; MICROORGANISMS;

ASSOCIATED BACTERIA; BIOFILM FORMATION; CENTERS FOR DISEASE CONTROL AND PREVENTIONS; EXPOSED TO; INHIBITORY CONCENTRATION; INTEGRATIVE APPROACH; MICROBIAL CELLS; NATURAL-ANTIMICROBIALS;

ANTIBIOTICS;

ANTIBIOTICS; ANTIMICROBIAL ACTIVITY; BACTERIUM; BIOFILM; CONCENTRATION (COMPOSITION); EXPERIMENTAL STUDY; INTEGRATED APPROACH; MEDICINE;

ANTIINFECTIVE AGENT;

BACTERIAL PHENOMENA AND FUNCTIONS; BIOFILM; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; NOMENCLATURE;

ANTI-BACTERIAL AGENTS; BACTERIAL PHYSIOLOGICAL PHENOMENA; BIOFILMS; MICROBIAL SENSITIVITY TESTS; TERMINOLOGY AS TOPIC;

EID: 85010215822     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.02508-16     Document Type: Short Survey

References (141)

1. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. https://doi.org/10.1128/CMR.15.2.167-193.2002
2. National Heart, Lung, and Blood Institute. 2002. Research on microbial biofilms (PA-03-047). National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
3. Costerton JW. 1999. Introduction to biofilm. Int J Antimicrob Agents 11:217-221. https://doi.org/10.1016/S0924-8579(99)00018-7
4. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138. https://doi.org/10.1016/S0140-6736(01) 05321-1
5. Flemming HC, Wingender J. 2010. The biofilm matrix. Nat Rev Microbiol 8:623-633. https://doi.org/10.1038/nrmicro2415
6. Mann EE, Wozniak DJ. 2012. Pseudomonas biofilm matrix composition and niche biology. FEMS Microbiol Rev 36:893-916. https://doi.org/10.1111/j.1574-6976.2011.00322.x
7. Beloin C, Renard S, Ghigo JM, Lebeaux D. 2014. Novel approaches to combat bacterial biofilms. Curr Opin Pharmacol 18:61-68. https://doi.org/10.1016/j.coph.2014.09.005
8. Vega NM, Gore J. 2014. Collective antibiotic resistance: mechanisms and implications. Curr Opin Microbiol 2:28-34. https://doi.org/10.1016/j.mib.2014.09.003
9. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 15:1663-1674. https://doi.org/10.2217/fmb.10.125
10. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. 2011. Staphylococcus aureus biofilms: properties, regulation and roles in human disease. Virulence 2:445-459. https://doi.org/10.4161/viru.2.5.17724
11. Driffield K, Miller K, Bostock JM, O'Neill AJ, Chopra I. 2008. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 61:1053-1056. https://doi.org/10.1093/jac/dkn044
12. Ghannoum M, O'Toole GA. 2004. Microbial biofilms. ASM Press, Washington, DC
13. Watnick P, Kolter R. 2000. Biofilm, city of microbes. J Bacteriol 182: 2675-2679. https://doi.org/10.1128/JB.182.10.2675-2679.2000
14. Kocianova S, Vuong C, Yao Y, Voyich JM, Fischer ER, DeLeo FR, Otto M. 2005. Key role of poly-γ-DL-glutamic acid in immune evasion and virulence of Staphylococcus epidermidis. J Clin Invest 115:688-694. https://doi.org/10.1172/JCI200523523
15. Wilkins M, Hall-Stoodley L, Allan RN, Faust SN. 2014. New approaches to the treatment of biofilm-related infections. J Infect 69:S47-S52. https://doi.org/10.1016/j.jinf.2014.07.014
16. van der Veen S, Abee T. 2011. Mixed species biofilms of Listeria monocytogenes and Lactobacillus plantarum show enhanced resistance to benzalkonium chloride and peracetic acid. Int J Food Microbiol 144: 421-431. https://doi.org/10.1016/j.ijfoodmicro.2010.10.029
17. Giaouris E, Chorianopoulos N, Doulgeraki A, Nychas GJ. 2013. Coculture with Listeria monocytogenes within a dual-species biofilm community strongly increases resistance of Pseudomonas putida to benzalkonium chloride. PLoS One 8:e77276. https://doi.org/10.1371/journal.pone.0077276
18. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230:13-18. https://doi.org/10.1016/S0378-1097(03)00856-5
19. Dawson CC, Intapa C, Jabra-Rizk MA. 2011. "Persisters": survival at the cellular level. PLoS Pathog 7:e1002121. https://doi.org/10.1371/journal .ppat.1002121
20. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. 2008. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 68:223-240. https://doi.org/10.1111/j.1365-2958.2008.06152.x
21. Zhang L, Mah TF. 2008. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol 190:4447-4452. https://doi.org/10.1128/JB.01655-07
22. Vikram A, Bomberger JM, Bibbya KJ. 2015. Efflux as a glutaraldehyde resistance mechanism in Pseudomonas fluorescens and Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 59:3433-3440. https://doi.org/10.1128/AAC.05152-14
23. Kvist M, Hancock V, Klemm P. 2008. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 74: 7376-7382. https://doi.org/10.1128/AEM.01310-08
24. Chen M, Yu Q, Sun H. 2013. Novel strategies for the prevention and treatment of biofilm related infections. Int J Mol Sci 14:18488-18501. https://doi.org/10.3390/ijms140918488
25. Vuotto C, Longo F, Donelli G. 2014. Probiotics to counteract biofilmassociated infections: promising and conflicting data. Int J Oral Sci 6:189-194. https://doi.org/10.1038/ijos.2014.52
26. Estrela AB, Abraham WR. 2010. Combining biofilm-controlling compounds and antibiotics as a promising new way to control biofilm infections. Pharmaceuticals (Basel) 3:1374-1393. https://doi.org/10 .3390/ph3051374
27. National Center for Complementary and Integrative Health. 2014. Frequently asked questions: name change. National Center for Complementary and Integrative Health (NCCIH), Bethesda, MD. https://nccih.nih.gov/news/name-change-faq
28. Rossi LM, Rangasamy P, Zhang J, Qiu X-Q, Wu GY. 2008. Research advances in the development of peptide antibiotics. J Pharm Sci 97: 1060-1070. https://doi.org/10.1002/jps.21053
29. Melo MN, Ferre R, Castanho MA. 2009. Antimicrobial peptides: linking partition, activity and high membrane bound concentrations. Nat Rev Microbiol 7:245-250. https://doi.org/10.1038/nrmicro2095
30. Jorge P, Lourenco A, Pereira MO. 2012. New trends in peptide-based anti-biofilm strategies: a review of recent achievements and bioinformatic approaches. Biofouling 28:1033-1061. https://doi.org/10.1080/08927014.2012.728210
31. Ma L, Liu X, Liang H, Che Z, Chen C, Dai H, Yu K, Liu M, Ma L, Yang CH, Song F, Wang Y, Zhang L. 2012. Effects of 14-alpha-lipoyl andrographolide on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 56:6088-6094. https://doi.org/10.1128/AAC.01119-12
32. Xu W, Zhu X, Tan T, Li W, Shan A. 2014. Design of embedded-hybrid antimicrobial peptides with enhanced cell selectivity and anti-biofilm activity. PLoS One 9:e98935. https://doi.org/10.1371/journal.pone .0098935
33. Tiwari SK, Noll KS, Cavera VL, Chikindas ML. 2015. Improved antimicrobial activities of synthetic-hybrid bacteriocins designed from enterocin E50-52 and pediocin PA-1. Appl Environ Microbiol 81:1661-1667. https://doi.org/10.1128/AEM.03477-14
34. Li L, Guo L, Lux R, Eckert R, Yarbrough D, He J, Anderson M, Shi WY. 2010. Targeted antimicrobial therapy against Streptococcus mutans establishes protective non-cariogenic oral biofilms and reduces subsequent infection. Int J Oral Sci 2:66-73. https://doi.org/10.4248/IJOS10024
35. He J, Anderson MH, Shi W, Eckert R. 2009. Design and activity of a 'dual-targeted' antimicrobial peptide. Int J Antimicrob Agents 33: 532-537. https://doi.org/10.1016/j.ijantimicag.2008.11.013
36. Wimley W, Hristova K. 2011. Antimicrobial peptides: successes, challenges and unanswered questions. J Membr Biol 239:27-34. https://doi.org/10.1007/s00232-011-9343-0
37. de la Fuente-Núñz C, Korolik V, Bains M, Nguyen U, Breidenstein EBM, Horsman S, Lewenza S, Burrows L, Hancock RE. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob Agents Chemother 56:2696-2704. https://doi.org/10.1128/AAC.00064-12
38. Overhage J, Campisano A, Bains M, Torfs ECW, Rehm BHA, Hancock REW. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76:4176-4182. https://doi.org/10.1128/IAI.00318-08
39. Dean S, Bishop B, van Hoek M. 2011. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol 11:114. https://doi.org/10.1186/1471-2180-11-114
40. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. 2002. A component of innate immunity prevents bacterial biofilm development. Nature 417: 552-555. https://doi.org/10.1038/417552a
41. Das T, Sharma PK, Busscher HJ, van der Mei HC, Krom BP. 2010. Role of extracellular DNA in initial bacterial adhesion and surface aggregation. Appl Environ Microbiol 76:3405-3408. https://doi.org/10.1128/AEM.03119-09
42. Altman H, Steinberg D, Porat Y, Mor A, Fridman D, Friedman M, Bachrach G. 2006. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J Antimicrob Chemother 58:198-201. https://doi.org/10.1093/jac/dkl181
43. Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, Meehl M, Cheung A, Götz F. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog 3:e102. https://doi.org/10.1371/journal.ppat .0030102
44. Eckert R, Brady KM, Greenberg EP, Qi F, Yarbrough DK, He J, McHardy I, Anderson MH, Shi W. 2006. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob Agents Chemother 50:3833-3838. https://doi.org/10.1128/AAC.00509-06
45. Minardi D, Ghiselli R, Cirioni O, Giacometti A, Kamysz W, Orlando F, Silvestri C, Parri G, Kamysz E, Scalise G, Saba V, Giovanni M. 2007. The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model. Peptides 28:2293-2298. https://doi.org/10.1016/j.peptides.2007.10.001
46. Herrmann G, Yang L, Wu H, Song Z, Wang H, Høiby N, Ulrich M, Molin S, Riethmüller J, Döring G. 2010. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 202:1585-1592. https://doi.org/10.1086/656788
47. Hirt H, Gorr S. 2013. Antimicrobial peptide GL13K is effective in reducing biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:4903-4910. https://doi.org/10.1128/AAC.00311-13
48. Dosler S, Karaaslan E. 2014. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides. Peptides 62:32-37. https://doi.org/10.1016/j.peptides.2014.09.021
49. Hirakura Y, Kobayashi S, Matsuzaki K. 2002. Specific interactions of the antimicrobial peptides cyclic β-sheet tachyplesin I with lipopolysaccharides. Biochim Biophys Acta 1562:32-36. https://doi.org/10.1016/S0005-2736(02)00358-9
50. Mataraci E, Dosler S. 2012. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillinresistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 56:6366-6371. https://doi.org/10.1128/AAC.01180-12
51. Dosler S, Mataraci E. 2013. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides 49:53-58. https://doi.org/10.1016/j.peptides.2013.08.008
52. Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Mocchegiani F, Silvestri C, Licci A, Skerlavaj B, Zanetti M, Saba V, Scalise G. 2006. Pre-treatment of central venous catheters with the cathelicidin BMAP-28 enhances the efficacy of antistaphylococcal agents in the treatment of experimental catheter-related infection. Peptides 27: 2104-2110. https://doi.org/10.1016/j.peptides.2006.03.007
53. Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Silvestri C, Orlando F, Kamysz W, Licci A, Nadolski P, Della Vittoria A, Lukasiak J, Scalise G, Saba V. 2007. Pretreatment with the protegrin IB-367 affects Grampositive biofilm and enhances the therapeutic efficacy of linezolid in animal models of central venous catheter infection. JPEN J Parenter Enteral Nutr 31:463-468. https://doi.org/10.1177/014860 7107031006463
54. 2 and Pal-Lys-Lys soaking alone and in combination with intraperitoneal vancomycin prevent vascular graft biofilm in a subcutaneous rat pouch model of staphylococcal infection. Peptides 28:1299-1303. https://doi.org/10.1016/j.peptides .2007.03.017
55. de la Fuente-Núñez C, Reffuveille F, Haney EF, Straus SK, Hancock REW. 2014. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog 10:e1004152. https://doi.org/10.1371/journal.ppat.1004152
56. de la Fuente-Núñez C, Reffuveille F, Mansour SC, Reckseidler-Zenteno SL, Hernández D, Brackman G, Coenye T, Hancock RE. 2015. D-Enantiomeric peptides that eradicate wild-type and multidrugresistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem Biol 22:196-205. https://doi.org/10.1016/j .chembiol.2015.01.002
57. Low CSF, White DC. 1989. Regulation of external polymer production in benthic microbial communities, p 228-238. In Cohen Y, Rosenberg E (ed), Microbial mat: physiological ecology of benthic microbial communities. American Society for Microbiology, Washington, DC
58. Bayles KW. 2007. The biological role of death and lysis in biofilm development. Nat Rev Microbiol 5:721-726. https://doi.org/10.1038/nrmicro1743
59. Cooksey KE, Wigglesworth-Cooksey B. 1995. Adhesion of bacteria and diatoms to surfaces in the sea: a review. Aquat Microb Ecol 9:87-96. https://doi.org/10.3354/ame009087
60. Ramasamy P, Zhang X. 2005. Effects of shear stress on the secretion of extracellular polymeric substances in biofilms. Water Sci Technol 52: 217-223
61. Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. 2009. Antimicrobial and antibiofilm efficacy of triclosan and DispersinB combination. J Antimicrob Chemother 64:88-93. https://doi.org/10.1093/jac/dkp158
62. Izano EA, Wang H, Ragunath C, Ramasubbu N, Kaplan JB. 2007. Detachment and killing of Aggregatibacter actinomycetemcomitans biofilms by dispersin B and SDS. J Dent Res 86:618-622. https://doi.org/10.1177/154405910708600707
63. Eckhart L, Fischer H, Barken KB, Tolker-Nielsen T, Tschachler E. 2007. DNase1L2 suppresses biofilm formation by Pseudomonas aeruginosa and Staphylococcus aureus. Br J Dermatol 156:1342-1345. https://doi.org/10.1111/j.1365-2133.2007.07886.x
64. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. 2002. Extracellular DNA required for bacterial biofilm formation. Science 295:1487. https://doi.org/10.1126/science.295.5559.1487
65. Kalpana BJ, Aarthy S, Pandian SK. 2012. Antibiofilm activity of α-amylase from Bacillus subtilis S8-18 against biofilm forming human bacterial pathogens. Appl Biochem Biotechnol 167:1778-1794. https://doi.org/10.1007/s12010-011-9526-2
66. Craigen B, Dashiff A, Kadouri DE. 2011. The use of commercially available alpha-amylase compounds to inhibit and remove Staphylococcus aureus biofilms. Open Microbiol J 5:21-31. https://doi.org/10.2174/1874285801105010021
67. Singh V, Verma N, Banerjee B, Vibha K, Haque S, Tripathi CK. 2015. Enzymatic degradation of bacterial biofilms using Aspergillus clavatus MTCC 1323. Microbiology 84:59-64. https://doi.org/10.1134/S0026261715010130
68. Kokai-Kun JF, Chanturiya T, Mond JJ. 2009. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 6:94-100. https://doi.org/10.1093/jac/dkp145
69. Alkawash MA, Soothill JS, Schiller NL. 2006. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 114:131-138. https://doi.org/10.1111/j.1600-0463.2006.apm_356.x
70. Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S, Izano EA. 2012. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 65:73-77. https://doi.org/10.1038/ja.2011.113
71. Tetz GV, Artemenko NK, Tetz VV. 2009. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother 53: 1204-1209. https://doi.org/10.1128/AAC.00471-08
72. Donelli G, Francolini I, Romoli D, Guaglianone E, Piozzi A, Ragunath C, Kaplan JB. 2007. Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm growth on polyurethanes. Antimicrob Agents Chemother 51:2733-2740. https://doi.org/10.1128/AAC.01249-06
73. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. 2003. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother 47:3407-3414. https://doi.org/10.1128/AAC.47.11.3407-3414.2003
74. Aguinaga A, Francés ML, Del Pozo JL, Alonso M, Serrera A, Lasa I, Leiva J. 2011. Lysostaphin and clarithromycin: a promising combination for the eradication of Staphylococcus aureus biofilms. Int J Antimicrob Agents 37:585-587. https://doi.org/10.1016/j.ijantimicag.2011.02.009
75. Kumar Shukla S, Rao TS. 2013. Dispersal of Bap-mediated Staphylococcus aureus biofilm by proteinase K. J Antibiot (Tokyo) 66:55-60. https://doi.org/10.1038/ja.2012.98
76. Uroz S, Dessaux Y, Oger P. 2009. Quorum sensing and quorum quenching: the yin and yang of bacterial communication. Chembiochem 10:205-216. https://doi.org/10.1002/cbic.200800521
77. Chen F, Gao Y, Chen X, Yu Z, Li X. 2013. Quorum quenching enzymes and their application in degrading signal molecules to block quorum sensing-dependent infection. Int J Mol Sci 14:17477-17500. https://doi.org/10.3390/ijms140917477
78. Francolini I, Norris P, Piozzi A, Donelli G, Stoodley P. 2004. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother 48:4360-4365. https://doi.org/10.1128/AAC.48.11.4360-4365.2004
79. Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G. 2007. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother 51:2226-2229. https://doi.org/10.1128/AAC .01097-06
80. O'Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. 2013. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci U S A 110:17981-17986. https://doi.org/10.1073/pnas.1316981110
81. Kim HS, Lee SH, Byun Y, Park HD. 2015. 6-Gingerol reduces Pseudomonas aeruginosa biofilm formation and virulence via quorum sensing inhibition. Sci Rep 5:8656. https://doi.org/10.1038/srep08656
82. Rasamiravaka T, Labtani Q, Duez P, El Jaziri M. 2015. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. Biomed Res Int 2015:759348. https://doi.org/10.1155/2015/759348
83. Rasmussen TB, Skindersoe ME, Bjarnsholt T, Phipps RK, Christensen KB, Jensen PO, Andersen JB, Koch B, Larsen TO, Hentzer M, Eberl L, Hoiby N, Givskov M. 2005. Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology 151:1325-1340. https://doi.org/10.1099/mic.0.27715-0
84. Roy V, Meyer MT, Smith JA, Gamby S, Sintim HO, Ghodssi R, Bentley WE. 2013. AI-2 analogs and antibiotics: a synergistic approach to reduce bacterial biofilms. Appl Microbiol Biotechnol 97:2627-2638. https://doi.org/10.1007/s00253-012-4404-6
85. Kiran S, Sharma P, Harjai K, Capalash N. 2011. Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa. Iran J Microbiol 3:1-12
86. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. 2011. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob Agents Chemother 55:2655-2661. https://doi.org/10.1128/AAC.00045-11
87. Zeng Z, Qian L, Cao L, Tan H, Huang Y, Xue X, Shen Y, Zhou S. 2008. Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of Pseudomonas aeruginosa. Appl Microbiol Biotechnol 79:119-126. https://doi.org/10.1007/s00253-008-1406-5
88. Zeng X, Liu X, Bian J, Pei G, Dai H, Polyak SW, Song F, Ma L, Wang Y, Zhang L. 2011. Synergistic effect of 14-alpha-lipoyl andrographolide and various antibiotics on the formation of biofilms and production of exopolysaccharide and pyocyanin by Pseudomonas aeruginosa. Antimicrob Agents Chemother 55:3015-3017. https://doi.org/10.1128/AAC.00575-10
89. Singh BN, Singh HB, Singh A, Singh BR, Mishra A, Nautiyal CS. 2012. Lagerstroemia speciosa fruit extract modulates quorum sensingcontrolled virulence factor production and biofilm formation in Pseudomonas aeruginosa. Microbiology 158:529-538. https://doi.org/10.1099/mic.0.052985-0
90. Jakobsen TH, van Gennip M, Phipps RK, Shanmugham MS, Christensen LD, Alhede M, Skindersoe ME, Rasmussen TB, Friedrich K, Uthe F, Jensen PØ, Moser C, Nielsen KF, Eberl L, Larsen TO, Tanner D, Høiby N, Bjarnsholt T, Givskov M. 2012. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob Agents Chemother 56:2314-2325. https://doi.org/10.1128/AAC.05919-11
91. Yang JY, Della-Fera MA, Nelson-Dooley C, Baile CA. 2006. Molecular mechanisms of apoptosis induced by ajoene in 3T3-L1 adipocytes. Obesity 14:388-397. https://doi.org/10.1038/oby.2006.52
92. Christensen LD, van Gennip M, Jakobsen TH, Alhede M, Hougen HP, Høiby N, Bjarnsholt T, Givskov M. 2012. Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model. J Antimicrob Chemother 67: 1198-1206. https://doi.org/10.1093/jac/dks002
93. Hammer KA, Carson CF, Riley TV. 1999. Antimicrobial activity of essential oils and other plant extracts. J Appl Microbiol 86:985-990. https://doi.org/10.1046/j.1365-2672.1999.00780.x
94. Nazzaro F, Fratianni F, De Martino L, Coppola R, De Feo V. 2013. Effect of essential oils on pathogenic bacteria. Pharm 6:1451-1474
95. Fabian D, Sabol M, Domaracka K, Bujnakova D. 2006. Essential oils-their antimicrobial activity against Escherichia coli and effect on intestinal cell viability. Toxicol In Vitro 20:1435-1445. https://doi.org/10.1016/j.tiv.2006.06.012
96. Warnke PH, Sherry E, Russo PA, Acil Y, Wiltfang J, Sivananthan S, Sprengel M, Roldàn JC, Schubert S, Bredee JP, Springer IN. 2006. Antibacterial essential oils in malodorous cancer patients: clinical observations in 30 patients. Phytomedicine 13:463-467. https://doi.org/10.1016/j.phymed.2005.09.012
97. Isman MB. 2000. Plant essential oils for pest and disease management. Crop Prot 19:603-608. https://doi.org/10.1016/S0261-2194(00)00079-X
98. Kavanaugh NL, Ribbeck K. 2012. Selected antimicrobial essential oils eradicate Pseudomonas spp. and Staphylococcus aureus biofilms. Appl Environ Microbiol 78:4057-4061. https://doi.org/10.1128/AEM.07499-11
99. Nostro A, Roccaro AS, Bisignano G, Marino A, Cannatelli MA, Pizzimenti FC, Cioni PL, Procopio F, Blanco AR. 2007. Effects of oregano, carvacrol and thymol on Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Med Microbiol 56:519-523. https://doi.org/10.1099/jmm.0 .46804-0
100. Brady A, Loughlin R, Gilpin D, Kearney P, Tunney M. 2006. In vitro activity of tea tree oil against clinical skin isolates of meticillin-resistant and-sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. J Med Microbiol 55: 1375-1380. https://doi.org/10.1099/jmm.0.46558-0
101. Yap PSX, Yiap BC, Ping HC, Lim SHE. 2014. Essential oils, a new horizon in combating bacterial antibiotic resistance. Open Microbiol J 8:6-14. https://doi.org/10.2174/1874285801408010006
102. Rosato A, Vitali C, De Laurentis N, Armenise D, Milillo MA. 2007. Antibacterial effect of some essential oils administered alone or in combination with norfloxacin. Phytomedicine 14:727-732. https://doi.org/10.1016/j.phymed.2007.01.005
103. Jafri H, Husain FM, Ahmad I. 2014. Antibacterial and antibiofilm activity of some essential oils and compounds against clinical strains of Staphylococcus aureus. J Biomed Ther Sci 1:65-71
104. Coelho FA, Pereira MO. 2013. Exploring new treatment strategies for Pseudomonas aeruginosa biofilm infections based on plant essential oils, p 83-89. In Méndez-Vilas A (ed), Microbial pathogens and strategies for combating them: science, technology and education, vol 1. Formatex Research Center, Badajoz, Spain
105. Cox SD, Gustafson JE, Mann CM, Markham JL, Liew YC, Hartland RP, Bell HC, Warmington JR, Wyllie SG. 1998. Tea tree oil causes K+ leakage and inhibits respiration in Escherichia coli. Lett Appl Microbiol 26:335-358. https://doi.org/10.1046/j.1472-765X.1998.00348.x
106. Langeveld WT, Veldhuizen EJA, Burt SA. 2014. Synergy between essential oil components and antibiotics: a review. Crit Rev Microbiol 40: 76-94. https://doi.org/10.3109/1040841X.2013.763219
107. Longbottom CJ, Carson CF, Hammer KA, Mee BJ, Riley TV. 2004. Tolerance of Pseudomonas aeruginosa to Melaleuca alternifolia (tea tree) oil is associated with the outer membrane and energy-dependent cellular processes. J Antimicrob Chemother 54:386-392. https://doi.org/10.1093/jac/dkh359
108. Cirino IC, Menezes-Silva SM, Silva HT, de Souza EL, Siqueira-Júnior JP. 2014. The essential oil from Origanum vulgare L. and its individual constituents carvacrol and thymol enhance the effect of tetracycline against Staphylococcus aureus. Chemotherapy 60:290-293. https://doi.org/10.1159/000381175
109. Hwang IS, Hwang JH, Choi H, Kim KJ, Lee DG. 2012. Synergistic effects between silver nanoparticles and antibiotics and the mechanisms involved. J Med Microbiol 61:1719-1726. https://doi.org/10.1099/jmm.0.047100-0
110. Martinez-Gutierrez F, Boegli L, Agostinho A, Sánchez EM, Bach H, Ruiz F, James G. 2013. Anti-biofilm activity of silver nanoparticles against different microorganisms. Biofouling 29:651-660. https://doi.org/10.1080/08927014.2013.794225
111. Kalishwaralal K, BarathManiKanth S, Pandian SR, Deepak V, Gurunathan S. 2010. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surf B Biointerfaces 79:340-344. https://doi.org/10.1016/j.colsurfb .2010.04.014
112. Chaudhari PR, Masurkar SA, Shidore VB, Kamble SP. 2012. Effect of biosynthesized silver nanoparticles on Staphylococcus aureus biofilm quenching and prevention of biofilm formation. Nano Micro Lett 4:34-39. https://doi.org/10.1007/BF03353689
113. Peulen TO, Wilkinson KJ. 2011. Diffusion of nanoparticles in a biofilm. Environ Sci Technol 45:3367-3373. https://doi.org/10.1021/es103450g
114. Gurunathan S, Han JW, Kwon DN, Kim JH. 2014. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res Lett 9:373. https://doi.org/10.1186/1556-276X-9-373
115. Su HL, Chou CC, Hung DJ, Lin SH, Pao IC, Lin JH, Huang FL, Dong RX, Lin JJ. 2009. The disruption of bacterial membrane integrity through ROS generation induced by nanohybrids of silver and clay. Biomaterials 9:5979-5987. https://doi.org/10.1016/j.biomaterials.2009.07.030
116. Habash MB, Park AJ, Vis EC, Harris RJ, Khursigara CM. 2014. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms. Antimicrob Agents Chemother 58:5818-5830. https://doi.org/10.1128/AAC.03170-14
117. Cihalova K, Chudobova D, Michalek P, Moulick A, Guran R, Kopel P, Adam V, Kizek R. 2015. Staphylococcus aureus and MRSA growth and biofilm formation after treatment with antibiotics and SeNPs. Int J Mol Sci 16:24656-24672. https://doi.org/10.3390/ijms161024656
118. Turovskiy Y, Noll KS, Chikindas ML. 2011. The etiology of bacterial vaginosis. J Appl Microbiol 110:1105-1128. https://doi.org/10.1111/j .1365-2672.2011.04977.x
119. Hymes SR, Randis TM, Sun TY, Ratner AJ. 2013. DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis 15:1491-1497
120. Algburi A, Volski A, Chikindas ML. 2015. Natural antimicrobials subtilosin and lauramide arginine ethyl ester synergize with conventional antibiotics clindamycin and metronidazole against biofilms of Gardnerella vaginalis but not against biofilms of healthy vaginal lactobacilli. FEMS Path Dis 73:pii=ftv018. https://doi.org/10.1093/femspd/ftv018
121. Turovskiy Y, Cheryian T, Algburi A, Wirawan RE, Takhistov P, Sinko PJ, Chikindas ML. 2012. Susceptibility of Gardnerella vaginalis biofilms to natural antimicrobials subtilosin, ε-poly-L-lysine, and lauramide arginine ethyl ester. Infect Dis Obstet Gynecol 2012:284762
122. Braga PC, Dal Sasso M, Culici M, Spallino A. 2010. Inhibitory activity of thymol on native and mature Gardnerella vaginalis biofilms: in vitro study. Arzneimittelforschung 60:675-681. https://doi.org/10.1055/s-0031-1296346
123. Sosto F, Benvenuti C, CANVA Study Group. 2010. Controlled study on thymol + eugenol vaginal douche versus econazole in vaginal candidiasis and metronidazole in bacterial vaginosis. Arzneimittelforschung 61:126-131. https://doi.org/10.1055/s-0031-1296178
124. Rabea EI, Badawy ME-T, Stevens CV, Smuagghe G, Steurbaut W. 2003. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 4:1457-1465. https://doi.org/10.1021/bm034130m
125. Dutta P, Dutta J, Tripathi VS. 2004. Chitin and chitosan: chemistry, properties and applications. J Sci Ind Res 63:20-31
126. Elsabee MZ, Morsi RE, Al-Sabagh AM. 2009. Surface active properties of chitosan and its derivatives. Colloids Surf B Biointerfaces 74:1-16. https://doi.org/10.1016/j.colsurfb.2009.06.021
127. Zhang A, Mu H, Zhang W, Cui G, Zhu J, Duan J. 2013. Chitosan coupling makes microbial biofilms susceptible to antibiotics. Sci Rep 3:3364. https://doi.org/10.1038/srep03364
128. Parker AC, Jennings JA, Bumgardner JD, Courtney HS, Lindner E, Haggard WO. 2013. Preliminary investigation of crosslinked chitosan sponges for tailorable drug delivery and infection control. J Biomed Mater Res B Appl Biomater 101:110-123. https://doi.org/10.1002/jbm .b.32822
129. Mahmoud HA, Melake NA, El-Semary MT. 2012. Bactericidal activity of various antibiotics versus tetracycline-loaded chitosan microspheres against Pseudomonas aeruginosa biofilms. Pharmaceut Anal Acta 15:1-9
130. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. 2006. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 188:7344-7353. https://doi.org/10.1128/JB.00779-06
131. Jennings JA, Courtney HS, Haggard WO. 2012. Cis-2-decenoic acid inhibits S. aureus growth and biofilm in vitro: a pilot study. Clin Orthop Relat Res 470:2663-2670. https://doi.org/10.1007/s11999-012-2388-2
132. Cirioni O, Giacometti A, Ghiselli R, Kamysz W, Orlando F, Mocchegiani F, Silvestri C, Licci A, Chiodi L, Lukasiak J, Saba V, Scalise G. 2006. Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 27:1210-1216. https://doi.org/10.1016/j.peptides.2005.10.007
133. Pompilio A, Crocetta V, Scocchi M, Pomponio S, Di Vincenzo V, Mardirossian M, Gherardi G, Fiscarelli E, Dicuonzo G, Gennaro R, Di Bonaventura G. 2012. Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiol 12:145. https://doi.org/10.1186/1471-2180-12-145
134. Chennupati SK, Chiu AG, Tamashiro E, Banks CA, Cohen MB, Bleier BS, Kofonow JM, Tam E, Cohen NA. 2009. Effects of an LL-37-derived antimicrobial peptide in an animal model of biofilm Pseudomonas sinusitis. Am J Rhinol Allergy 23:46-51. https://doi.org/10.2500/ajra.2009.23.3261
135. Carmen JC, Nelson JL, Beckstead BL, Runyan CM, Robison RA, Schaalje GB, Pitt WG. 2004. Ultrasonic-enhanced gentamicin transport through colony biofilms of Pseudomonas aeruginosa and Escherichia coli. J Infect Chemother 10:193-199. https://doi.org/10.1007/s10156-004-0319-1
136. Gerdt JP, Blackwell HE. 2014. Competition studies confirm two major barriers that can preclude the spread of resistance to quorum-sensing inhibitors in bacteria. ACS Chem Biol 9:2291-2299. https://doi.org/10.1021/cb5004288
137. Bovenkamp GL, Zanzen U, Krishna KS, Hormes J, Prange A. 2013. X-ray absorption near-edge structure (XANES) spectroscopy study of the interaction of silver ions with Staphylococcus aureus, Listeria monocytogenes, and Escherichia coli. Appl Environ Microbiol 79:6385-6390. https://doi.org/10.1128/AEM.01688-13
138. Estrela AB, Heck MG, Abraham WR. 2009. Novel approaches to control biofilm infections. Curr Med Chem 16:1512-1530. https://doi.org/10.2174/092986709787909640
139. Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172:1487-1490. https://doi.org/10.1164/rccm.200504-613PP
140. Loose C. 2007. The production, design and application of antimicrobial peptides. Ph.D. thesis. Massachusetts Institute of Technology, Cambridge, MA
141. Patel DN, Ho HK, Tan LL, Tan M-MB, Zhang Q, Low M-Y, Chan CL, Koh HL. 2015. Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products. Front Pharmacol 6:25